Dr. Simrit Parmar is a Tenured Associate Professor in the Department of Lymphoma & Myeloma as well as Experimental Therapeutics at MD Anderson Cancer Center in Houston, Texas. She received her hematology/oncology fellowship training at Northwestern University and completed a bone marrow transplant fellowship at MD Anderson Cancer Center. Dr. Parmar developed an allogeneic cord blood-derived regulatory T-cell (Treg) therapy platform in her research laboratories at MD Anderson Cancer Center. This T-cell technology has now been licensed to the biotech company, Cellenkos Inc. Dr. Parmar has published her findings in peer-reviewed journals, and her research has been translated into several clinical trials including i) Phase 1/ 2 trial of 3rd party cord blood regulatory T cells for the prevention of GVHD, ii) Phase 1 trial of CK0801 for treatment of bone marrow failure, iii) Randomized, placebo control, double-blinded, multicenter trial of CK0802 for treatment of COVID-19 ARDS, iii) Randomized, placebo control, double-blinded, multicenter trial of CK0803 for treatment of Amyotrophic Lateral Sclerosis and iv) Phase 1b trial of CK0804 as add-on therapy to ruxolitinib for the treatment of myelofibrosis. Her research has been funded by peer-reviewed grants, including from the National Institute of Health (NIH) as well as the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Parmar was also the proud recipient of the inaugural R. Lee Clark Fellowship award in 2014. Additionally, she is actively involved with the global academic program as well as the MD Anderson Cancer Network program. Dr. Parmar is one of the founding members of the Asia Pacific Hematology Consortium, which focuses on advancing the field of hematology/oncology through continued education, collaboration, and fostering innovations. She also chaired the radiation injury treatment network (RITN) committee at MD Anderson Cancer Center and served on the board of the Global Affairs Committee for the Foundation for Accreditation of Cellular Therapy (FACT).